Novel Drug Delivery Systems Market Segmentation:
Route of Administration Segment Analysis
The injectable delivery systems segment is estimated to account for the largest share of 36% in the novel drug delivery systems market over the discussed timeframe. Injectable delivery systems are the primary route of delivery for biologics, vaccines, and other complex molecules that need to be delivered with an exact dosage. The CDC states that vaccination campaigns globally have skyrocketed, increasing the need for an advanced injectable NDDS to directly improve patient compliance and safety. The significant uses of injectable systems also include controlled release and targeted delivery, which offer reduced side effects and ultimately improve therapeutic effect. Also, injectable systems continue to draw heightened regulatory scrutiny, particularly for injectable product safety.
Type Segment Analysis
The controlled release systems segment is poised to dominate the novel drug delivery systems market with a share of 29% during the analyzed period. Controlled release technologies are central to the management of chronic diseases due to their ability to provide the same drug level over a longer time course, resulting in a higher level of efficacy and adherence to the drug regimen. As mentioned by the World Health Organization (WHO), this approach facilitates a reduction in the number of times a patient has to take a dose, therefore improving the outcome of the treatment, and reducing the burden on the healthcare system. This segment continues to expand with the rising incidence of diabetes, cardiovascular diseases, and other chronic conditions that require drugs to be continuously delivered.
Application Segment Analysis
The oncology segment is poised to dominate the novel drug delivery systems market with a share of 31% during the analyzed period. The oncology segment generates excessive revenue driven by a growing global incidence of cancer. The WHO shows a steadily increasing incidence of cancer, which drives demand for targeted NDDS that confine drug delivery to tumors to avoid systemic toxicity. The therapeutic index is improved, and quality of life is enhanced for patients with novel delivery systems, which continues to drive innovation and implementation of new protocols for oncology treatment.
Our in-depth analysis of the global novel drug delivery systems market includes the following segments:
|
Segments |
Subsegments |
|
Type |
|
|
Route of Administration |
|
|
Technology |
|
|
Application |
|
|
Carrier Material |
|
|
End User |
|
